155 related articles for article (PubMed ID: 9243618)
1. 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs.
Johnson KW; Schaus JM; Durkin MM; Audia JE; Kaldor SW; Flaugh ME; Adham N; Zgombick JM; Cohen ML; Branchek TA; Phebus LA
Neuroreport; 1997 Jul; 8(9-10):2237-40. PubMed ID: 9243618
[TBL] [Abstract][Full Text] [Related]
2. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
Mitsikostas DD; Tfelt-Hansen P
Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751
[TBL] [Abstract][Full Text] [Related]
3. Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog.
Adham N; Bard JA; Zgombick JM; Durkin MM; Kucharewicz S; Weinshank RL; Branchek TA
Neuropharmacology; 1997; 36(4-5):569-76. PubMed ID: 9225282
[TBL] [Abstract][Full Text] [Related]
4. Lasmiditan mechanism of action - review of a selective 5-HT
Clemow DB; Johnson KW; Hochstetler HM; Ossipov MH; Hake AM; Blumenfeld AM
J Headache Pain; 2020 Jun; 21(1):71. PubMed ID: 32522164
[TBL] [Abstract][Full Text] [Related]
5. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).
Martin GR; Robertson AD; MacLennan SJ; Prentice DJ; Barrett VJ; Buckingham J; Honey AC; Giles H; Moncada S
Br J Pharmacol; 1997 May; 121(2):157-64. PubMed ID: 9154322
[TBL] [Abstract][Full Text] [Related]
6. The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs.
Williamson DJ; Hill RG; Shepheard SL; Hargreaves RJ
Br J Pharmacol; 2001 Aug; 133(7):1029-34. PubMed ID: 11487512
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan.
Nelson DL; Phebus LA; Johnson KW; Wainscott DB; Cohen ML; Calligaro DO; Xu YC
Cephalalgia; 2010 Oct; 30(10):1159-69. PubMed ID: 20855361
[TBL] [Abstract][Full Text] [Related]
8. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine.
John GW; Pauwels PJ; Perez M; Halazy S; Le Grand B; Verscheure Y; Valentin JP; Palmier C; Wurch T; Chopin P; Marien M; Kleven MS; Koek W; Assie MB; Carilla-Durand E; Tarayre JP; Colpaert FC
J Pharmacol Exp Ther; 1999 Jul; 290(1):83-95. PubMed ID: 10381763
[TBL] [Abstract][Full Text] [Related]
9. Involvement of 5-HT1B receptors in triptan-induced contractile responses in guinea-pig isolated iliac artery.
Jähnichen S; Radtke OA; Pertz HH
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jul; 370(1):54-63. PubMed ID: 15185063
[TBL] [Abstract][Full Text] [Related]
10. G-protein activation at 5-HT1A receptors by the 5-ht1F ligand LY334370 in guinea-pig brain sections and recombinant cell lines.
Dupuis DS; Colpaert FC; Pauwels PJ
Br J Pharmacol; 1998 May; 124(2):283-90. PubMed ID: 9641544
[TBL] [Abstract][Full Text] [Related]
11. Targeting the 5-HT
Huang PC; Yang FC; Chang CM; Yang CP
Prog Brain Res; 2020; 255():99-121. PubMed ID: 33008517
[TBL] [Abstract][Full Text] [Related]
12. Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system; expression, release and interactions with 5-HT
Edvinsson JCA; Maddahi A; Christiansen IM; Reducha PV; Warfvinge K; Sheykhzade M; Edvinsson L; Haanes KA
J Headache Pain; 2022 Feb; 23(1):26. PubMed ID: 35177004
[TBL] [Abstract][Full Text] [Related]
13. Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine.
Phebus LA; Johnson KW; Zgombick JM; Gilbert PJ; Van Belle K; Mancuso V; Nelson DL; Calligaro DO; Kiefer AD; Branchek TA; Flaugh ME
Life Sci; 1997; 61(21):2117-26. PubMed ID: 9395253
[TBL] [Abstract][Full Text] [Related]
14. The selectivity of MDL 74,721 in models of neurogenic versus vascular components of migraine.
Petty MA; Elands J; Johnson MP; Linnik MD; Hamel E; Moskowitz MA; Lee WS; McCarty DR; Hibert M; Baron BM
Eur J Pharmacol; 1997 Oct; 336(2-3):127-36. PubMed ID: 9384224
[TBL] [Abstract][Full Text] [Related]
15. The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT(1B/1D) receptor agonist.
Gupta P; Butler P; Shepperson NB; McHarg A
Eur J Pharmacol; 2000 Jun; 398(1):73-81. PubMed ID: 10856450
[TBL] [Abstract][Full Text] [Related]
16. Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis.
Cutrer FM; Yu XJ; Ayata G; Moskowitz MA; Waeber C
Neuropharmacology; 1999 Jul; 38(7):1043-53. PubMed ID: 10428423
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of action of the 5-HT1B/1D receptor agonists.
Tepper SJ; Rapoport AM; Sheftell FD
Arch Neurol; 2002 Jul; 59(7):1084-8. PubMed ID: 12117355
[TBL] [Abstract][Full Text] [Related]
18. Serotonin in migraine: theories, animal models and emerging therapies.
Johnson KW; Phebus LA; Cohen ML
Prog Drug Res; 1998; 51():219-44. PubMed ID: 9949863
[TBL] [Abstract][Full Text] [Related]
19. N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy.
Xu YC; Johnson KW; Phebus LA; Cohen M; Nelson DL; Schenck K; Walker CD; Fritz JE; Kaldor SW; LeTourneau ME; Murff RE; Zgombick JM; Calligaro DO; Audia JE; Schaus JM
J Med Chem; 2001 Nov; 44(24):4031-4. PubMed ID: 11708905
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. A comment.
Maggioni F; Pini LA; Zanchin G
Cephalalgia; 2011 Jul; 31(9):1061. PubMed ID: 21511951
[No Abstract] [Full Text] [Related]
[Next] [New Search]
